Applied Filter(s) Clear Filter


Type:

Industry:

Therapy Area: Ophthalmological Disorder

Category:

Fuchs’ Endothelial Corneal Dystrophy Market

Report ID: PNPH1255 Industry: Pharma & Biotech Therapy Area: Ophthalmological Disorder

The Fuchs Endothelial Corneal Dystrophy Market is predicted to grow throughout the forecast period of 2023-2030. In order to assume growth at a CAGR of 8.40% throughout the previously predicted period, Pharmanucleus undertakes a market study.

Global Exophthalmos Market

Report ID: PNPH1209 Industry: Pharma & Biotech Therapy Area: Ophthalmological Disorder

The Exophthalmos Market report, published by Pharmanucleus, provides a comprehensive analysis of the Exophthalmos condition, including its historical and forecasted epidemiology, as well as market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report covers current treatment practices, emerging drugs, market share of individual therapies, and the market size from 2023 to 2030, segmented by major markets.

Acute Ocular Pain Market

Report ID: PNPH1189 Industry: Pharma & Biotech Therapy Area: Ophthalmological Disorder

The Acute Ocular Pain market is projected to grow significantly in the coming years. The market, which was valued at USD 195.2 Mn in 2023, is anticipated to reach USD 270.07 Mn by 2033, reflecting a compound annual growth rate (CAGR) of 3.3% during the forecast period of 2024 to 2033.

Why Choose Us

Inclusion of Pre-clinical Molecules

Other than an extensive coverage of clinical and commercial drugs, our reports also provide details about pre-clinical molecules!

Start-up
Profiling

One of our marquee services We profile relevant start-up companies in the market.

KOL
Insight's

Get access to reliable data our insights and analyses are backed by Key Opinion Leaders in the field.

Specialized in Healthcare

Our team comprises of industry specialists and research experts from life sciences area holding degree in Medicine, Doctor of Pharmacy, M.Sc. in Pharmacy, Pharma MBAs, and Biotechnology.